Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is expected to continue growing and reaching profitability, with a Buy rating and positive outlook due to their unique technology, favorable clinical outcomes, and experienced leadership team. Despite potential risks in the form of competition and reimbursement, the company has shown strong financial results and is targeting a large global market with a hybrid sales model. However, it's important to monitor potential risks, such as their concentrated customer base, as the company continues to expand and grow.

Bears say

Carlsmed is a commercial-stage company with a limited product portfolio and relatively low revenue growth forecasted for the next few years, making it less attractive for potential investors. This, combined with the company's slow progress towards achieving profitability and potential challenges in achieving cash flow breakeven on < $200 million in revenue, could contribute to a negative outlook on the stock. Additionally, while management expects significant revenue growth and multiple product launches, there are potential risks and uncertainties in achieving these targets.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.